Detection of Anti-Cardiolipin and Anti-beta 2glycoprotein I Antibodies Differs between Platforms without Influence on Association with Clinical Symptoms

Walid Chayoua, Hilde Kelchtermans, Gary W. Moore, Jean-Christophe Gris, Jacek Musial, Denis Wahl, Stephane Zuily, Francesca Gianniello, Pierre Fontana, Jasper Remijn, Rolf T. Urbanus, Bas de Laat, Katrien M. J. Devreese*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)797-806
Number of pages10
JournalThrombosis and Haemostasis
Volume119
Issue number5
DOIs
Publication statusPublished - May 2019

Keywords

  • solid phase assays
  • anti-cardiolipin
  • beta 2 glycoprotein I
  • epitope
  • thrombosis
  • EXTERNAL QUALITY-ASSURANCE
  • ANTIPHOSPHOLIPID SYNDROME
  • LABORATORY DIAGNOSIS
  • DOMAIN-I
  • STANDARDIZATION
  • ASSAYS
  • BETA(2)-GLYCOPROTEIN-I
  • PERFORMANCE
  • THROMBOSIS
  • CONSENSUS

Cite this

Chayoua, W., Kelchtermans, H., Moore, G. W., Gris, J-C., Musial, J., Wahl, D., Zuily, S., Gianniello, F., Fontana, P., Remijn, J., Urbanus, R. T., de Laat, B., & Devreese, K. M. J. (2019). Detection of Anti-Cardiolipin and Anti-beta 2glycoprotein I Antibodies Differs between Platforms without Influence on Association with Clinical Symptoms. Thrombosis and Haemostasis, 119(5), 797-806. https://doi.org/10.1055/s-0039-1679901